1. Home
  2. ALLO vs TRUE Comparison

ALLO vs TRUE Comparison

Compare ALLO & TRUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • TRUE
  • Stock Information
  • Founded
  • ALLO 2017
  • TRUE 2005
  • Country
  • ALLO United States
  • TRUE United States
  • Employees
  • ALLO N/A
  • TRUE N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • TRUE Computer Software: Programming Data Processing
  • Sector
  • ALLO Health Care
  • TRUE Technology
  • Exchange
  • ALLO Nasdaq
  • TRUE Nasdaq
  • Market Cap
  • ALLO 431.9M
  • TRUE 397.2M
  • IPO Year
  • ALLO 2018
  • TRUE 2014
  • Fundamental
  • Price
  • ALLO $2.07
  • TRUE $4.21
  • Analyst Decision
  • ALLO Buy
  • TRUE Strong Buy
  • Analyst Count
  • ALLO 12
  • TRUE 3
  • Target Price
  • ALLO $10.06
  • TRUE $4.50
  • AVG Volume (30 Days)
  • ALLO 2.5M
  • TRUE 219.6K
  • Earning Date
  • ALLO 11-07-2024
  • TRUE 11-06-2024
  • Dividend Yield
  • ALLO N/A
  • TRUE N/A
  • EPS Growth
  • ALLO N/A
  • TRUE N/A
  • EPS
  • ALLO N/A
  • TRUE N/A
  • Revenue
  • ALLO $43,000.00
  • TRUE $170,678,000.00
  • Revenue This Year
  • ALLO N/A
  • TRUE $13.25
  • Revenue Next Year
  • ALLO N/A
  • TRUE $19.93
  • P/E Ratio
  • ALLO N/A
  • TRUE N/A
  • Revenue Growth
  • ALLO 26.47
  • TRUE 10.77
  • 52 Week Low
  • ALLO $1.83
  • TRUE $2.56
  • 52 Week High
  • ALLO $5.78
  • TRUE $4.62
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 41.06
  • TRUE 51.42
  • Support Level
  • ALLO $1.83
  • TRUE $4.10
  • Resistance Level
  • ALLO $2.09
  • TRUE $4.34
  • Average True Range (ATR)
  • ALLO 0.14
  • TRUE 0.22
  • MACD
  • ALLO -0.01
  • TRUE -0.03
  • Stochastic Oscillator
  • ALLO 30.38
  • TRUE 33.87

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About TRUE TrueCar Inc.

TrueCar Inc is a data-driven online platform operating on common technology infrastructure, powered by proprietary data and analytics. It also customizes and operates its platform for affinity group marketing partners, including financial institutions like PenFed and American Express; membership-based organizations like Consumer Reports, AARP, Sam's Club, and AAA; and employee buying programs for large enterprises such as IBM and Walmart. TrueCar enables users to obtain market-based pricing data on new and used cars, and to connect with its network of TrueCar Certified Dealers.

Share on Social Networks: